We are thrilled to announce the publication of our latest research: “Dynamics of humoral and cellular response to three doses of the anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.”
While the risk of Sars-CoV-2 infection has decreased, it remains a concern for vulnerable populations, particularly patients with hematological malignancies and older individuals.
In this paper we explored the antibody and cellular response to the BNT162b2 vaccine in patients with hematological malignancies (FHM).
The findings reveal a substantial response to the BNT162b2 vaccine in FHM, showing increasing antibody levels after the third dose, accompanied by a discernible T-cell response.
Given the severe outcomes observed in FHM patients who contracted the virus, our recommendation is for oncologic patients to receive regular anti-COVID vaccinations, even in periods of lower infection risk.
We express our gratitude to our dedicated researchers, Mirco Compagnone, Eugenia Principato, and Eleonora Pinto, whose significant contributions were instrumental in determining the neutralizing power of antibodies in the subject population.
Congratulations to all coauthors for achieving this noteworthy result!
